Tenaya's TN-301 Outperforms Approved DMD Drug in Preclinical Study, Targets Phase 2
TNYA has more than doubled off its 52-week low of $0.36 on elevated volume (2.0× avg).
Summary
Tenaya Therapeutics presented encouraging preclinical data for its highly selective HDAC6 inhibitor, TN-301, at the Muscular Dystrophy Association's Clinical & Scientific Conference 2026. The data demonstrated that TN-301 outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and correcting key drivers of Duchenne Muscular Dystrophy (DMD) cardiomyopathy in both in vitro and in vivo models. This positive pipeline update follows a recent significant research collaboration with Alnylam Pharmaceuticals earlier this month. For a small-cap biotech, strong preclinical data, particularly showing superiority to an approved drug, is a material de-risking event for a key pipeline asset. The company plans to advance TN-301 toward Phase 2 clinical development for DMD and heart failure with preserved ejection fraction (HFpEF). Investors will now monitor for updates on the IND filing and the initiation of these planned Phase 2 clinical trials.
At the time of this announcement, TNYA was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.3M. The 52-week trading range was $0.36 to $2.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.